Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.

Ciudin A, Johansson E, Zimner-Rapuch S, Dimitriadis GK, Bertrand M, Curteis T, Clark LJ, Fan L, Sapin H, Bergmann JF

Diabetes, obesity & metabolism19 Jun 2025Cited by 11 (Europe PMC)

PMID40537987PMCIDPMC12326929DOI10.1111/dom.16508PepBankPUB-40537987

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study13

13 results from studies that gave the peptide. 13 results from people.

01HumanOther designEfficacy outcome
In adults with obesity or overweight and type 2 diabetes, indirect comparison showed greater weight reduction with tirzepatide 10 and 15 mg than with semaglutide 2.4 mg.
In plain wordsIn adults with type 2 diabetes and excess weight, an indirect comparison found tirzepatide cut weight more than semaglutide.
Peptide
Tirzepatide
Outcome
DecreaseWeight reduction versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg (indirect, via placebo)
Outcome group
Body weight · Metabolic and weight
Studied dose
10 and 15 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Tirzepatide 10 and 15 mg were associated with statistically significant greater reductions in weight, BMI and HbA1c versus semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2.
Summary · context
Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity.
Report a problemFND-4053798701
02HumanOther designEfficacy outcome
In adults with obesity or overweight and type 2 diabetes, indirect comparison showed greater BMI reduction with tirzepatide 10 and 15 mg than with semaglutide 2.4 mg.
In plain wordsIn adults with type 2 diabetes and excess weight, an indirect comparison found tirzepatide cut BMI more than semaglutide.
Peptide
Tirzepatide
Outcome
DecreaseBMI reduction versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg (indirect, via placebo)
Outcome group
Body weight · Metabolic and weight
Studied dose
10 and 15 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Tirzepatide 10 and 15 mg were associated with statistically significant greater reductions in weight, BMI and HbA1c versus semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2.
Summary · context
Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity.
Report a problemFND-4053798702
03HumanOther designEfficacy outcome
In adults with obesity or overweight and type 2 diabetes, indirect comparison showed greater HbA1c reduction with tirzepatide 10 and 15 mg than with semaglutide 2.4 mg.
In plain wordsIn adults with type 2 diabetes and excess weight, an indirect comparison found tirzepatide lowered HbA1c more than semaglutide.
Peptide
Tirzepatide
Outcome
DecreaseHbA1c reduction versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg (indirect, via placebo)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
10 and 15 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Tirzepatide 10 and 15 mg were associated with statistically significant greater reductions in weight, BMI and HbA1c versus semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2.
Summary · context
Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity.
Report a problemFND-4053798703
04HumanOther designEfficacy outcome
In adults with obesity or overweight and type 2 diabetes, indirect comparison showed greater odds of at least 5% weight reduction with tirzepatide 15 mg than with semaglutide 2.4 mg.
In plain wordsIn adults with type 2 diabetes, an indirect comparison found better odds of losing 5% of weight with tirzepatide 15 mg than semaglutide.
Peptide
Tirzepatide
Outcome
IncreaseOdds of at least 5% weight reduction
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg (indirect, via placebo)
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Tirzepatide 15 mg was associated with statistically significant greater odds versus semaglutide of ≥5% and ≥15% weight reduction
2 context sentences(design, population, supporting numbers)
Summary · context
This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2.
Summary · context
Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity.
Report a problemFND-4053798704
05HumanOther designEfficacy outcome
In adults with obesity or overweight and type 2 diabetes, indirect comparison showed greater odds of at least 15% weight reduction with tirzepatide 15 mg than with semaglutide 2.4 mg.
In plain wordsIn adults with type 2 diabetes, an indirect comparison found better odds of losing 15% of weight with tirzepatide 15 mg than semaglutide.
Peptide
Tirzepatide
Outcome
IncreaseOdds of at least 15% weight reduction
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg (indirect, via placebo)
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Tirzepatide 15 mg was associated with statistically significant greater odds versus semaglutide of ≥5% and ≥15% weight reduction
2 context sentences(design, population, supporting numbers)
Summary · context
This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2.
Summary · context
Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity.
Report a problemFND-4053798705
06HumanOther designEfficacy outcome
In adults with obesity or overweight and type 2 diabetes, indirect comparison showed a significantly greater improvement in waist circumference with tirzepatide 15 mg than with semaglutide 2.4 mg.
In plain wordsIn adults with type 2 diabetes and excess weight, an indirect comparison found tirzepatide 15 mg improved waist size more than semaglutide.
Peptide
Tirzepatide
Outcome
DecreaseWaist circumference versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg (indirect, via placebo)
Outcome group
Body weight · Metabolic and weight
Studied dose
15 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Tirzepatide 15 mg was associated with statistically significant greater odds versus semaglutide of ≥5% and ≥15% weight reduction and statistically significant improvements in several cardiometabolic risk factors, including waist circumference, fasting plasma glucose and triglycerides.
2 context sentences(design, population, supporting numbers)
Summary · context
This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2.
Summary · context
Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity.
Report a problemFND-4053798706
07HumanOther designEfficacy outcome
In adults with obesity or overweight and type 2 diabetes, indirect comparison showed a significantly greater improvement in fasting plasma glucose with tirzepatide 15 mg than with semaglutide 2.4 mg.
In plain wordsIn adults with type 2 diabetes and excess weight, an indirect comparison found tirzepatide 15 mg improved fasting glucose more than semaglutide.
Peptide
Tirzepatide
Outcome
DecreaseFasting plasma glucose versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg (indirect, via placebo)
Outcome group
Glycemic control · Metabolic and weight
Studied dose
15 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Tirzepatide 15 mg was associated with statistically significant greater odds versus semaglutide of ≥5% and ≥15% weight reduction and statistically significant improvements in several cardiometabolic risk factors, including waist circumference, fasting plasma glucose and triglycerides.
2 context sentences(design, population, supporting numbers)
Summary · context
This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2.
Summary · context
Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity.
Report a problemFND-4053798707
08HumanOther designEfficacy outcome
In adults with obesity or overweight and type 2 diabetes, indirect comparison showed a significantly greater improvement in triglycerides with tirzepatide 15 mg than with semaglutide 2.4 mg.
In plain wordsIn adults with type 2 diabetes and excess weight, an indirect comparison found tirzepatide 15 mg improved triglycerides more than semaglutide.
Peptide
Tirzepatide
Outcome
DecreaseTriglycerides versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg (indirect, via placebo)
Outcome group
Lipids · Metabolic and weight
Studied dose
15 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Tirzepatide 15 mg was associated with statistically significant greater odds versus semaglutide of ≥5% and ≥15% weight reduction and statistically significant improvements in several cardiometabolic risk factors, including waist circumference, fasting plasma glucose and triglycerides.
2 context sentences(design, population, supporting numbers)
Summary · context
This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2.
Summary · context
Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity.
Report a problemFND-4053798708
09HumanOther designEfficacy outcome
In adults with obesity or overweight and type 2 diabetes, indirect comparison showed only a non-significant trend toward greater HDL improvement with tirzepatide 10 and 15 mg than with semaglutide 2.4 mg.
In plain wordsIn adults with type 2 diabetes and excess weight, an indirect comparison found no clear difference in HDL cholesterol between tirzepatide and semaglutide.
Peptide
Tirzepatide
Outcome
No significant changeHDL cholesterol versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg (indirect, via placebo)
Outcome group
Lipids · Metabolic and weight
Studied dose
10 and 15 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Both tirzepatide doses showed non-significant trends of greater improvements in high-density lipoprotein, low-density lipoprotein, systolic blood pressure and diastolic blood pressure versus semaglutide as well as a generally comparable safety profile to semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2.
Summary · context
Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity.
Report a problemFND-4053798709
10HumanOther designEfficacy outcome
In adults with obesity or overweight and type 2 diabetes, indirect comparison showed only a non-significant trend toward greater LDL improvement with tirzepatide 10 and 15 mg than with semaglutide 2.4 mg.
In plain wordsIn adults with type 2 diabetes and excess weight, an indirect comparison found no clear difference in LDL cholesterol between tirzepatide and semaglutide.
Peptide
Tirzepatide
Outcome
No significant changeLDL cholesterol versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg (indirect, via placebo)
Outcome group
Lipids · Metabolic and weight
Studied dose
10 and 15 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Both tirzepatide doses showed non-significant trends of greater improvements in high-density lipoprotein, low-density lipoprotein, systolic blood pressure and diastolic blood pressure versus semaglutide as well as a generally comparable safety profile to semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2.
Summary · context
Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity.
Report a problemFND-4053798710
11HumanOther designEfficacy outcome
In adults with obesity or overweight and type 2 diabetes, indirect comparison showed only a non-significant trend toward greater systolic blood pressure improvement with tirzepatide 10 and 15 mg than with semaglutide 2.4 mg.
In plain wordsIn adults with type 2 diabetes and excess weight, an indirect comparison found no clear difference in systolic blood pressure between tirzepatide and semaglutide.
Peptide
Tirzepatide
Outcome
No significant changeSystolic blood pressure versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg (indirect, via placebo)
Outcome group
Blood pressure · Cardiovascular
Studied dose
10 and 15 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Both tirzepatide doses showed non-significant trends of greater improvements in high-density lipoprotein, low-density lipoprotein, systolic blood pressure and diastolic blood pressure versus semaglutide as well as a generally comparable safety profile to semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2.
Summary · context
Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity.
Report a problemFND-4053798711
12HumanOther designEfficacy outcome
In adults with obesity or overweight and type 2 diabetes, indirect comparison showed only a non-significant trend toward greater diastolic blood pressure improvement with tirzepatide 10 and 15 mg than with semaglutide 2.4 mg.
In plain wordsIn adults with type 2 diabetes and excess weight, an indirect comparison found no clear difference in diastolic blood pressure between tirzepatide and semaglutide.
Peptide
Tirzepatide
Outcome
No significant changeDiastolic blood pressure versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg (indirect, via placebo)
Outcome group
Blood pressure · Cardiovascular
Studied dose
10 and 15 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Both tirzepatide doses showed non-significant trends of greater improvements in high-density lipoprotein, low-density lipoprotein, systolic blood pressure and diastolic blood pressure versus semaglutide as well as a generally comparable safety profile to semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2.
Summary · context
Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity.
Report a problemFND-4053798712
13HumanOther designSafety outcome
In adults with obesity or overweight and type 2 diabetes, indirect comparison showed a generally comparable safety profile for tirzepatide 10 and 15 mg and semaglutide 2.4 mg.
In plain wordsIn adults with type 2 diabetes and excess weight, an indirect comparison found tirzepatide and semaglutide had a generally similar safety profile.
Peptide
Tirzepatide
Outcome
No significant changeSafety profile versus semaglutide
Study
n: not reported in source
Comparator
Semaglutide 2.4 mg (indirect, via placebo)
Outcome group
Adverse events · Whole body
Studied dose
10 and 15 mg once weekly · subcutaneousAs given in this study (human).
Source sentences
Summary
Both tirzepatide doses showed non-significant trends of greater improvements in high-density lipoprotein, low-density lipoprotein, systolic blood pressure and diastolic blood pressure versus semaglutide as well as a generally comparable safety profile to semaglutide.
2 context sentences(design, population, supporting numbers)
Summary · context
This indirect treatment comparison (ITC) compared the efficacy and safety of tirzepatide with semaglutide for managing obesity or overweight in participants with type 2 diabetes (T2D), informed by the pivotal trials SURMOUNT-2 and STEP 2.
Summary · context
Bucher ITCs compared tirzepatide 10 and 15 mg once-weekly (QW) to semaglutide 2.4 mg QW via placebo, all adjunct to a reduced-calorie diet and increased physical activity.
Report a problemFND-4053798713

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 3Current
11 Oct 2026, 00:04 UTC
Study results updated
Version 2
9 Oct 2026, 03:07 UTC
Study data updated · source update from Europe PMC
Version 1
9 Oct 2026, 03:06 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.

Indirect comparative efficacy and safety of tirzepatide 10 and 15 mg versus semaglutide 2.4 mg for the management of obesity and overweight in patients with type 2 diabetes.

Summary

Results from this study13

Version history

Subjects

Publication types

MeSH terms

Keywords